Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Classical hematology 1

Conditions

Sarcoma 35Osteosarcoma 22Central Nervous System Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Ovarian Neoplasms 5Head and Neck Neoplasms 5Glioblastoma 5Colorectal Neoplasms 5Colonic Neoplasms 5Pancreatic Neoplasms 4Neuroblastoma 4Gliosarcoma 4Glioma 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Astrocytoma 4Wilms Tumor 3Sarcoma, Ewing 3Rhabdomyosarcoma 3Rectal Neoplasms 3Neuroectodermal Tumors, Primitive, Peripheral 3Neoplasms 3Neoplasm Metastasis 3Melanoma 3Esophageal Neoplasms 3Ependymoma 3Desmoplastic Small Round Cell Tumor 3Choroid Plexus Neoplasms 3Carcinoma, Ovarian Epithelial 3

Interventions

Melphalan 3Antilymphocyte Serum 3fludarabine phosphate 2Radiotherapy 2Methylprednisolone 2Cyclophosphamide 2Busulfan 2thymoglobulin 1Whole-Body Irradiation 1SRA737 1Mycophenolic Acid 1Gemcitabine 1Filgrastim 1Cyclosporine 1Cord Blood Stem Cell Transplantation 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fanconi Anemia × Cisplatin × Sarcoma × Clear all
NCT02797977 2023-06-22

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Sierra Oncology LLC - a GSK company

Phase 1/2 Completed
153 enrolled
Classical hematologySarcomaThoracic

Fanconi Anemia, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡